Reviva Pharmaceuticals Holdings Operating Cash Flow Growth & History (RVPH)
Reviva Pharmaceuticals Holdings's operating cash flow was −$24.6M for fiscal 2025.
View full Reviva Pharmaceuticals Holdings company overviewReviva Pharmaceuticals Holdings annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$24.6M | $8.9M | — |
| 2024 | 2024-12-31 | −$33.5M | −$5.2M | — |
| 2023 | 2023-12-31 | −$28.3M | −$9.4M | — |
| 2022 | 2022-12-31 | −$19.0M | −$8.3M | — |
| 2021 | 2021-12-31 | −$10.7M | −$6.6M | — |
| 2020 · Dec 31 | 2020-12-31 | −$4.1M | −$3.8M | — |
| 2020 · Feb 29 | 2020-02-29 | −$426,591 | −$205,722 | — |
| 2019 · Dec 31 | 2019-12-31 | −$218,444 | — | — |
| 2019 · Feb 28 | 2019-02-28 | −$220,869 | — | — |
Reviva Pharmaceuticals Holdings quarterly operating cash flow
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$2.1M | $2.9M | — |
| Q1 2026 | 2026-03-31 | −$3.8M | $4.4M | — |
| Q4 2025 | 2025-12-31 | −$5.8M | $3.3M | — |
| Q3 2025 | 2025-09-30 | −$5.6M | −$1.3M | — |
| Q2 2025 | 2025-06-30 | −$5.0M | $3.5M | — |
| Q1 2025 | 2025-03-31 | −$8.2M | $3.5M | — |
| Q4 2024 | 2024-12-31 | −$9.1M | −$224,052 | — |
| Q3 2024 | 2024-09-30 | −$4.2M | $1.9M | — |
| Q2 2024 | 2024-06-30 | −$8.5M | −$3.2M | — |
| Q1 2024 | 2024-03-31 | −$11.7M | −$3.8M | — |
| Q4 2023 | 2023-12-31 | −$8.9M | −$4.2M | — |
| Q3 2023 | 2023-09-30 | −$6.2M | −$2.2M | — |
| Q2 2023 | 2023-06-30 | −$5.3M | −$1.3M | — |
| Q1 2023 | 2023-03-31 | −$8.0M | −$1.7M | — |
| Q4 2022 | 2022-12-31 | −$4.7M | −$788,481 | — |
| Q3 2022 | 2022-09-30 | −$4.0M | −$1.7M | — |
| Q2 2022 | 2022-06-30 | −$4.0M | −$2.7M | — |
| Q1 2022 | 2022-03-31 | −$6.3M | −$3.2M | — |
| Q4 2021 | 2021-12-31 | −$3.9M | — | — |
| Q3 2021 · Sep 30 | 2021-09-30 | −$2.3M | −$1.6M | — |
| Q2 2021 · Jun 30 | 2021-06-30 | −$1.3M | −$986,008 | — |
| Q1 2021 · Mar 31 | 2021-03-31 | −$3.1M | −$3.1M | — |
| Q3 2021 · Nov 30 | 2020-11-30 | −$213,692 | −$136,763 | — |
| Q2 2021 · Sep 30 | 2020-09-30 | −$715,640 | — | — |
| Q2 2021 · Aug 31 | 2020-08-31 | −$271,608 | −$209,159 | — |
| Q1 2021 · Jun 30 | 2020-06-30 | −$354,733 | — | — |
| Q1 2021 · May 31 | 2020-05-31 | −$35,457 | $3,906 | — |
| Q1 2020 · Mar 31 | 2020-03-31 | −$60,662 | — | — |
| Q4 2020 | 2020-02-29 | −$247,850 | −$159,940 | — |
| Q3 2020 | 2019-11-30 | −$76,929 | −$36,319 | — |
| Q2 2020 | 2019-08-31 | −$62,449 | $41,559 | — |
| Q1 2020 · May 31 | 2019-05-31 | −$39,363 | −$51,022 | — |
| Q4 2019 | 2019-02-28 | −$87,910 | — | — |
| Q3 2019 | 2018-11-30 | −$40,610 | — | — |
| Q2 2019 | 2018-08-31 | −$104,008 | — | — |
| Q1 2019 | 2018-05-31 | $11,659 | — | — |
Reviva Pharmaceuticals Holdings operating cash flow trends
Over the last five fiscal years, Reviva Pharmaceuticals Holdings's operating cash flow decreased from −$4.1M to −$24.6M, a change of −$20.5M. The latest reported quarter, Q2 2026, shows −$2.1M.
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Reviva Pharmaceuticals Holdings source filings ↗